Literature DB >> 12970341

Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein.

Mario Salmona1, Michela Morbin, Tania Massignan, Laura Colombo, Giulia Mazzoleni, Raffaella Capobianco, Luisa Diomede, Florian Thaler, Luca Mollica, Giovanna Musco, Joseph J Kourie, Orso Bugiani, Deepak Sharma, Hideyo Inouye, Daniel A Kirschner, Gianluigi Forloni, Fabrizio Tagliavini.   

Abstract

Prion protein (PrP) amyloid formation is a central feature of genetic and acquired forms of prion disease such as Gerstmann-Sträussler-Scheinker disease (GSS) and variant Creutzfeldt-Jakob disease. The major component of GSS amyloid is a PrP fragment spanning residues approximately 82-146. To investigate the determinants of the physicochemical properties of this fragment, we synthesized PrP-(82-146) and variants thereof, including entirely and partially scrambled peptides. PrP-(82-146) readily formed aggregates that were partially resistant to protease digestion. Peptide assemblies consisted of 9.8-nm-diameter fibrils having a parallel cross-beta-structure. Second derivative of infrared spectra indicated that PrP-(82-146) aggregates are primarily composed of beta-sheet (54%) and turn (24%) which is consistent with their amyloid-like properties. The peptide induced a remarkable increase in plasma membrane microviscosity of primary neurons. Modification of the amino acid sequence 106-126 caused a striking increase in aggregation rate, with formation of large amount of protease-resistant amorphous material and relatively few amyloid fibrils. Alteration of the 127-146 region had even more profound effects, with the inability to generate amyloid fibrils. These data indicate that the intrinsic properties of PrP-(82-146) are dependent upon the integrity of the C-terminal region and account for the massive deposition of PrP amyloid in GSS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970341     DOI: 10.1074/jbc.M307295200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Heterologous stacking of prion protein peptides reveals structural details of fibrils and facilitates complete inhibition of fibril growth.

Authors:  Ronald S Boshuizen; Veronica Schulz; Michela Morbin; Giulia Mazzoleni; Rob H Meloen; Johannes P M Langedijk
Journal:  J Biol Chem       Date:  2009-03-19       Impact factor: 5.157

2.  Design of metastable β-sheet oligomers from natively unstructured peptide.

Authors:  Marcos J Guerrero-Muñoz; Diana L Castillo-Carranza; Urmi Sengupta; Mark A White; Rakez Kayed
Journal:  ACS Chem Neurosci       Date:  2013-10-14       Impact factor: 4.418

3.  Molecular conformation and dynamics of the Y145Stop variant of human prion protein in amyloid fibrils.

Authors:  Jonathan J Helmus; Krystyna Surewicz; Philippe S Nadaud; Witold K Surewicz; Christopher P Jaroniec
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-24       Impact factor: 11.205

4.  Natural and synthetic prion structure from X-ray fiber diffraction.

Authors:  Holger Wille; Wen Bian; Michele McDonald; Amy Kendall; David W Colby; Lillian Bloch; Julian Ollesch; Alexander L Borovinskiy; Fred E Cohen; Stanley B Prusiner; Gerald Stubbs
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-28       Impact factor: 11.205

5.  Structural studies of truncated forms of the prion protein PrP.

Authors:  William Wan; Holger Wille; Jan Stöhr; Amy Kendall; Wen Bian; Michele McDonald; Sarah Tiggelaar; Joel C Watts; Stanley B Prusiner; Gerald Stubbs
Journal:  Biophys J       Date:  2015-03-24       Impact factor: 4.033

6.  Determination of amyloid core structure using chemical shifts.

Authors:  Lukasz Skora; Markus Zweckstetter
Journal:  Protein Sci       Date:  2012-10-26       Impact factor: 6.725

7.  Conserved amyloid core structure of stop mutants of the human prion protein.

Authors:  Markus Zweckstetter
Journal:  Prion       Date:  2013-02-13       Impact factor: 3.931

8.  Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration.

Authors:  Clive Bate; Mourad Tayebi; Alun Williams
Journal:  Mol Neurodegener       Date:  2010-04-08       Impact factor: 14.195

9.  Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro.

Authors:  Clive Bate; Mourad Tayebi; Mario Salmona; Luisa Diomede; Alun Williams
Journal:  Neurotox Res       Date:  2009-07-31       Impact factor: 3.911

10.  Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines.

Authors:  Clive Bate; Mourad Tayebi; Luisa Diomede; Mario Salmona; Alun Williams
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.